Clinical trial

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04620135

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Netarsudil ophthalmic solution 0.02% Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Ripasudil hydrochloride hydrate ophthalmic solution 0.4% Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-11-30

PhasePHASE3

Conditions

Primary Open Angle Glaucomaunresolved

Ocular Hypertensionverified · MONDO: ocular hypertension

Interventions

Netarsudil ophthalmic solution 0.02%DRUG

Ripasudil hydrochloride hydrate ophthalmic solution 0.4%DRUG

Sponsors & collaborators

Aerie Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04620135 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.